Ocumension Therapeutics (HKG: 1477), a leading ophthalmology specialist in China, has announced that its histamine H1 receptor-targeted drug Zerviate (OT-1001) has been granted marketing approval in China with priority review status. The drug is indicated for the treatment of itching symptoms associated with allergic conjunctivitis.
Zerviate, originally developed by the France-based pharmaceutical firm Nicox SA, is an innovative formulation of cetirizine, which has already received market approval in the United States. In March 2019, Nicox granted Ocumension exclusive rights for the development and commercialization of Zerviate in Greater China. This licensing agreement was expanded a year later to include 11 additional countries in Southeast Asia.- Flcube.com
